Poxel (STU:7PO) Net Interest Margin (Bank Only) %

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

STU:7PO Poxel SA STU:7PO
37 GF Score
Price €0.19
GF Value €1.09
Valuation Possible Value Trap
! 6 Warning Signs
View Full Analysis

What is Poxel Net Interest Margin (Bank Only) %?

Net Interest Margin (Bank Only) % only applies to banks.

STU:7PO
37GF Score
Poxel SA STU:7PO
Net Interest Margin (Bank Only) % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Is Poxel (STU:7PO) Overvalued in 2026?

Based on GuruFocus' analysis, Poxel stock appears to be undervalued. The current stock price of €0.19 is trading 82.4% below its estimated GF Value™ of €1.09. GuruFocus considers Poxel to be Possible Value Trap.

Key valuation signals for STU:7PO:

  • Net Interest Margin (Bank Only) %:
  • GF Value™: €1.09 vs. price of €0.19 (82.4% below fair value)
  • GF Score™: 37/100 with 6 warning signs

No single metric tells the full story. See the STU:7PO stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Poxel Business Description

Address 259/261 Avenue Jean Jaures, Immeuble le Sunway, Lyon, FRA, 69007
Poxel SA is a biopharmaceutical company. It is focused on the development of novel treatments for metabolic diseases, including type 2 diabetes and liver diseases, such as nonalcoholic steatohepatitis (NASH) and rare disorders (ALD/AMN). It has developed a portfolio of drug candidates, including its candidates: Imeglimin, for the treatment of type 2 diabetes, and PXL770 and PXL065, for the treatment of NASH.
37GF Score

Get the complete analysis for STU:7PO

Net Interest Margin (Bank Only) % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.19
Price
€1.09
GF Value